Skip to main content
SpringerLink
Log in

Mechanisms of Tumor Evasion

  • Chapter
Tumor Immunology and Cancer Vaccines

Part of the book series: Cancer Treatment and Research ((CTAR,volume 123))

Abstract

The results from in vitro immunological experiments, murine tumor models and patients with cancer clearly demonstrate that tumors have multiple mechanisms to evade the immune response. During the early stages of tumor development malignant cells can be poor stimulators, present poor targets or become resistant to the innate immune response, while at later stages, progressively growing tumors impair the adaptive immune response by blocking the maturation and function of antigen presenting cells and causing alterations in T cell signal transduction and function. Preliminary results also suggest a correlation between some of these changes and an increased metastatic potential of the tumor cells, a diminished response to immunotherapy, and poor prognosis. Carefully coordinated basic research studies and clinical immunotherapy trials will be required to fully determine the impact on the outcome of the disease and the response to treatment. However, understanding the mechanisms used by tumor cells to evade the immune system could result in new therapeutic approaches for preventing and/or reversing these immune alterations and have the potential of improving the current results of immunotherapy trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nauts, H.C. 1977. Bacterial vaccine therapy of cancer. Dev Biol Stand 38:487–494.

    PubMed  CAS  Google Scholar 

  2. Prehn, R.T., and J.M. Main. 1957. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18:759–778.

    Google Scholar 

  3. Eggers, A.E., and J.R. Wunderlich. 1975. Suppressor cells in tumor-bearing mice capable of nonspecific blocking of in vitro immunization against transplant antigens. J Immunol 114:1554–1556.

    PubMed  CAS  Google Scholar 

  4. Fefer, A., J.L. McCoy, K. Perk, and J.P. Glynn. 1968. Immunologic, virologic, and pathologic studies of regression of autochthonous Moloney sarcoma virus-induced tumors in mice. Cancer Res 28:1577–1585.

    PubMed  CAS  Google Scholar 

  5. Jaroslow, B.N., K.M. Suhrbier, R.J. Fry, and S.A. Tyler. 1975. In vitro suppression of immunocompetent cells by lymphomas from aging mice. J Natl Cancer Inst 54:1427–1432.

    PubMed  CAS  Google Scholar 

  6. Hersh, E.M., and J.J. Oppenheim. 1965. Impaired in vitro lymphocyte transformation in Hodgkin’s disease. N Engl J Med 273:1006–1012.

    Article  PubMed  CAS  Google Scholar 

  7. Fisher, R.I., V.T. DeVita, Jr., F. Bostick, C. Vanhaelen, D.M. Howser, S.M. Hubbard, and R.C. Young. 1980. Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin’s disease. Ann Intern Med 92:595–599.

    PubMed  CAS  Google Scholar 

  8. Hellstrom, I., H.O. Sjogren, G. Warner, and K.E. Hellstrom. 1971. Blocking of cell-mediated tumor immunity by sera from patients with growing neoplasms. Int J Cancer 7:226–237.

    Article  PubMed  CAS  Google Scholar 

  9. Catalona, W.J., J.K. Smolev, and J.I. Harty. 1975. Prognostic value of host immunocompetence in urologic cancer patients. J Urol 114:922–926.

    PubMed  CAS  Google Scholar 

  10. Alberola, V., A. Gonzalez-Molina, A. Trenor, B. San Martin, A. Lluch, F. Palau, J. Marin, and F.J. Garcia-Conde. 1985. Mechanism of suppression of the depressed lymphocyte response in lung cancer patients. Allergol Immunopathol (Madr) 13:213–219.

    CAS  Google Scholar 

  11. Jerrells, T.R., J.H. Dean, G.L. Richardson, J.L. McCoy, and R.B. Herberman. 1978. Role of suppressor cells in depression of in vitro lymphoproliferative responses of lung cancer and breast cancer patients. J Natl Cancer Inst 61:1001–1009.

    PubMed  CAS  Google Scholar 

  12. Burnet, F.M. 1970. The concept of immunological surveillance. Prog Exp Tumor Res 13:1–27.

    PubMed  CAS  Google Scholar 

  13. Ikeda, H., L.J. Old, and R.D. Schreiber. 2002. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13:95–109.

    Article  PubMed  CAS  Google Scholar 

  14. Dighe, A.S., E. Richards, L.J. Old, and R.D. Schreiber. 1994. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1(6):447–56.

    Article  PubMed  CAS  Google Scholar 

  15. Dunn, G.P., A.T. Bruce, H. Ikeda, L.J. Old, and R.D. Schreiber. 2002 Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998.

    Article  PubMed  CAS  Google Scholar 

  16. Khong, H.T., and N.P. Restifo. 2002. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3:999–1005.

    Article  PubMed  CAS  Google Scholar 

  17. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu Rev Immunol 12:991–1045.

    PubMed  CAS  Google Scholar 

  18. Davis, S.J., S. Ikemizu, E.J. Evans, L. Fugger, T.R. Bakker, and P.A. van der Merwe. 2003. The nature of molecular recognition by T cells. Nat Immunol 4:217–224.

    Article  PubMed  CAS  Google Scholar 

  19. Marincola, F.M., E.M. Jaffee, D.J. Hicklin, and S. Ferrone. 2000. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181–273.

    PubMed  CAS  Google Scholar 

  20. Ferrone, S. (guest ed.). 2002. Tumour immune escape. Semin Cancer Biol 12.

    Google Scholar 

  21. Hicklin, D.J., F.M. Marincola, and S. Ferrone. 1999. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5:178–186.

    Article  PubMed  CAS  Google Scholar 

  22. Fukusato, T., M.A. Gerber, S.N. Thung, S. Ferrone, and F. Schaffner. 1986. Expression of HLA class I antigens on hepatocytes in liver disease. Am J Pathol 123:264–270.

    PubMed  CAS  Google Scholar 

  23. Kurokohchi, K. M., Carrington, D.L. Mann, T.B. Simonis, M.A. Alexander-Miller, S.M. Feinstone, T. Akatsuka, and J.A. Berzofsky. 1996. Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma. Hepatology 23:1181–1188.

    Article  PubMed  CAS  Google Scholar 

  24. Bi, Y. J., Zhang, Z. Hong, J. Huang, J. Chen, X. Wang, and S. Ferrone. 2002. Association of HLA class I antigen expression in human hepatocellar carcinoma with improved prognosis. Tissue Antigens 59Suppl. 2:105–106.

    Google Scholar 

  25. Wetzler. M.M.R., S.J. Baer, K. Stewart, L. Donohue, C.C. Ford, E.A. Stewart, Repasky, and S. Ferrone. 2001. HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. Leukemia 15:128–133.

    Article  PubMed  CAS  Google Scholar 

  26. Cabrera, T., G. Pedrajas, J.M. Cozar, A. Garrido, J. Vicente, M. Tallada, and F. Garrido. 2003. HLA class I expression in bladder carcinomas. Tissue Antigens 62:324–327.

    Article  PubMed  CAS  Google Scholar 

  27. Lehmann, F., M. Marchand, P. Hainaut, P. Pouillart, X. Sastre, H. Ikeda, T. Boon, and P.G. Coulie. 1995. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25:340–347.

    Article  PubMed  CAS  Google Scholar 

  28. Restifo, N.P., F.M. Marincola, Y. Kawakami, J. Taubenberger, J.R. Yannelli, and S.A. Rosenberg. 1996. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88:100–108.

    Article  PubMed  CAS  Google Scholar 

  29. Garcia-Lora, A., I. Algarra, J.J. Gaforio, F. Ruiz-Cabello, and F. Garrido. 2001. Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. Int J Cancer 91:109–119.

    Article  PubMed  CAS  Google Scholar 

  30. Lopez-Nevot, M.A., F. Esteban, A. Ferron, J. Gutierrez, M.R. Oliva, C. Romero, C. Huelin, F. Ruiz-Cabello, and F. Garrido. 1989. HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br J Cancer 59:221–226.

    PubMed  CAS  Google Scholar 

  31. Torres, M.J., F. Ruiz-Cabello, A. Skoudy, G. Berrozpe, P. Jimenez, A. Serrano, F.X. Real, and F. Garrido. 1996. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens 47:372–381.

    Article  PubMed  CAS  Google Scholar 

  32. Cordon-Cardo, C., Z. Fuks, M. Drobnjak, C. Moreno, L. Eisenbach, and M. Feldman. 1991. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 51: 6372–6380.

    PubMed  CAS  Google Scholar 

  33. Klein, B., T. Klein, M. Konichezky, A. Nyska, E. Livini, I. Levine, R. Zamir, O. Kooperman, and H. Lurie. 1990. The expression of HLA class I antigens in germ cell testicular cancer. Am J Clin Pathol 93:202–207.

    PubMed  CAS  Google Scholar 

  34. Ruiz-Cabello, F., M.A. Lopez Nevot, J. Gutierrez, M.R. Oliva, C. Romero, A. Ferron, F. Estebanj C. Huelin, M.A. Piris, and C. Rivas. 1989. Phenotypic expression of histocompatibility antigens in human primary tumours and metastases. Clin Exp Muetastasis 7:213–226.

    Article  CAS  Google Scholar 

  35. Kelly, L.M., and D.G. Gilliland. 2002. Genetics of myeloid leukemias. Annu. Rev. Genomics. Hum. Genet 3:179–198.

    Article  PubMed  CAS  Google Scholar 

  36. List, A.F., C.M. Spier, T.P. Miller, and T.M. Grogan. 1993. Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence. Leukemia 7:398–403.

    PubMed  CAS  Google Scholar 

  37. Seliger, B., M.J. Maeurer, and S. Ferrone. 2000. Antigen-processing machinery breakdown and tumor growth. Immunol Today 21:455–464.

    Article  PubMed  CAS  Google Scholar 

  38. Brasanac, D., C.A. Muller, G.A. Muller, J. Hadzi-Dzokic, and J. Markovic-Lipkovski. 1999. HLA class I antigens expression in renal cell carcinoma: histopathological and clinical correlation. J Exp Clin Cancer Res 18:505–510.

    PubMed  CAS  Google Scholar 

  39. Grandis, J.R., D.M. Falkner, M.F. Melhem, W.E. Gooding, S.D. Drenning, and P.A. Morel. 2000. Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences. Clin Cancer Res 6:2794–2802.

    PubMed  CAS  Google Scholar 

  40. Levin. I., T. Klein, J. Goldstein, O. Kuperman, J. Kanetti, B. Klein. 1991. Expression of class I histocompatibility antigens in transitional cell carcinoma of the urinary bladder in relation to survival. Cancer 68:2591–2594.

    Article  PubMed  CAS  Google Scholar 

  41. Klein, B., I. Levin, and T. Klein. 1996. HLA class I antigen expression in human solid tumors. Isr J Med Sci 32:1238–1243.

    PubMed  CAS  Google Scholar 

  42. Zia, A., F.W. Schildberg, and I. Funke. 2001. MHC class I negative phenotype of disseminated tumor cells in bone marrow is associated with poor survival in R0M0 breast cancer patients. Int J Cancer 93:566–570.

    Article  PubMed  CAS  Google Scholar 

  43. Levin, I., T. Klein, O. Kuperman, S. Segal, J. Shapira, R. Gal, Y. Hart, and B. Klein. 1994. The expression of HLA class I antigen in prostate cancer in relation to tumor differentiation and patient survival. Cancer Detect Prev 18:443–445.

    PubMed  CAS  Google Scholar 

  44. Jackson, P.A., M.A. Green, C.G. Marks, R.J. King, R. Hubbard, and M.G. Cook. 1996. Lymphocyte subset infiltration patterns and HLA antigen status in colorectal carcinomas and adenomas. Gut 38:85–89.

    PubMed  CAS  Google Scholar 

  45. Jager, M.J., H.M. Hurks, J. Levitskaya, and R. Kiessling. 2002. HLA expression in uveal melanoma: there is no rule without some exception. Hum Immunol 63:444–451.

    Article  PubMed  CAS  Google Scholar 

  46. Yano, T., Y. Fukuyama, H. Yokoyama, S. Kuninaka, H. Asoh, Y. Katsuda, and Y. Ichinose. 1998. HLA class I and class II expression of pulmonary adenocarcinoma cells and the influence of interferon gamma. Lung Cancer 20:185–190.

    Article  PubMed  CAS  Google Scholar 

  47. Garcia-Plata, D., E. Mozos, L. Carrasco, and R. Solana. 1993. HLA molecule expression in cutaneous squamous cell carcinomas: an immunopathological study and clinical-immunohistopathological correlations. Histol Histopathol 8:219–226.

    PubMed  CAS  Google Scholar 

  48. Koukourakis, M.I., A. Giatromanolaki, F. Guddo, L. Kaklamanis, M. Vignola, S. Kakolyris, H. Turley, V. Georgoulias, G. Bonsignore, K.C. Gatter, and A.L. Harris. 2000. c-erbB-2 and episialin challenge host immune response by HLA class I expression in human non-small-cell lung cancer. J Immunother 23:104–114.

    Article  PubMed  CAS  Google Scholar 

  49. Medeiros, L.J., A.B. Gelb, K. Wolfson, R. Doggett, B. McGregor, R.S. Cox, S.J. Horning, and R.A. Warnke. 1993. Major histocompatibility complex class I and class II antigen expression in diffuse large cell and large cell immunoblastic lymphomas. Absence of a correlation between antigen expression and clinical outcome. Am J Pathol 143:1086–1097.

    PubMed  CAS  Google Scholar 

  50. Maio, M., M. Altomonte, R. Tatake, R.A. Zeff, and S. Ferrone. 1991. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. J Clin Invest 88:282–289.

    PubMed  CAS  Google Scholar 

  51. Pende, D., L. Accame, L. Pareti, A. Mazzocchi, A. Moretta, G. Parmiani, and L. Moretta. 1998. the susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles. Eur J Immunol 28:2384–2394.

    Article  PubMed  CAS  Google Scholar 

  52. Garrido, F., and I. Algarra. 2001. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83:117–158.

    PubMed  CAS  Google Scholar 

  53. Serrano, A., S. Tanzarella, I. Lionello, R. Mendez, C. Traversari, F. Ruiz-Cabello, and F. Garrido. 2001. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment. Int J Cancer 94:243–251.

    Article  PubMed  CAS  Google Scholar 

  54. Giorda, E., L. Sibilio, A. Martayan, S. Moretti, I. Venturo, M. Mottolese, G.B. Ferrara, S. Cappellacci, L. Eibenschutz, C. Catricala, P. Grammatico, and P. Giacomini. 2003. The antigen processing machinery of class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells. Cancer Res 63:4119–4127.

    PubMed  CAS  Google Scholar 

  55. Fernandez, M.A., F. Ruiz-Cabello, M.R. Oliva, T. Cabrera, P. Jimenez, M.A. Lopez Nevot, and F. Garrido. 2000. Beta2-microglobulin gene mutation is not a common mechanism of HLA class I total loss in human tumors. Int J Clin Lab Res 30:87–92.

    Article  PubMed  CAS  Google Scholar 

  56. Feenstra, M., E. Rozemuller, K. Duran, I. Stuy, J. van den Tweel, P. Slootweg, R. de Weger, and M. Tilanus. 1999. Mutation in the beta 2m gene is not a frequent event in head and neck squamous cell carcinomas. Hum Immunol 60:697–706.

    Article  PubMed  CAS  Google Scholar 

  57. Yewdell, J. (guest ed.). 2002. Generating peptide ligands for MHC class I molecules. Mol Immunol 39.

    Google Scholar 

  58. Goodfellow, P.N., E.A. Jones, V. Van Heyningen, E. Solomon, M. Bobrow, V. Miggiano, and W.F. Bodmer. 1975. The beta 2-microglobulin gene is on chromosome 15 and not in the HLA region. Nature 254:267–269.

    Article  PubMed  CAS  Google Scholar 

  59. Jordanova, E.S., S.A. Riemersma, K. Philippo, E. Schuuring, and P.M. Kluin. 2003. Beta2-microglobulin aberrations in diffuse large B-cell lymphoma of the testis and the central nervous system. Int J Cancer 103:393–398.

    Article  PubMed  CAS  Google Scholar 

  60. McEvoy, C.R., R. Seshadri, A.A. Morley, and F.A. Firgaira. 2002. Frequency and genetic basis of MHC, beta-2-microglobulin and MEMO-1 loss of heterozygosity in sporadic breast cancer. Tissue Antigens 60:235–243.

    Article  PubMed  CAS  Google Scholar 

  61. Maleno, I., M.A. Lopez-Nevot, T. Cabrera, J. Salinero, and F. Garrido. 2002. Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother 51:389–396.

    Article  PubMed  CAS  Google Scholar 

  62. Paschen, A., R.M. Mendez, P. Jimenez, A. Sucker, F. Ruiz-Cabello, M. Song, F. Garrido, and D. Schadendorf. 2003. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 103:759–767.

    Article  PubMed  CAS  Google Scholar 

  63. Seliger, B., T. Cabrera, F. Garrido, and S. Ferrone. 2002. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12:3–13.

    Article  PubMed  CAS  Google Scholar 

  64. Lengauer, C., K.W. Kinzler, and B. Vogelstein. 1998. Genetic instabilities in human cancers. Nature 396:643–649.

    Article  PubMed  CAS  Google Scholar 

  65. Palmisano, G.L., M.P. Pistillo, P. Capanni, C. Pera, G. Nicolo, S. Salvi, L. Perdelli, G. Pasciucco, and G.B. Ferrara. 2001. Investigation of HLA class I downregulation in breast cancer by RT-PCR. Hum Immunol 62:133–139.

    Article  PubMed  CAS  Google Scholar 

  66. Nie, Y., G. Yang, Y. Song, X. Zhao, C. So, J. Liao, L.D. Wang, and C.S. Yang. 2001. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 22:1615–1623.

    Article  PubMed  CAS  Google Scholar 

  67. Fonsatti, E., L. Sigalotti, S. Coral, F. Colizzi, M. Altomonte, and M. Maio. 2003. Methylation-regulated expression of HLA class I antigens in melanoma. Int J Cancer 105:430–431.

    Article  PubMed  CAS  Google Scholar 

  68. Wang, Z., F.M. Marincola, L. Rivoltini, G. Parmiani, and S. Ferrone. 1999. Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. J Exp Med 190:205–215.

    Article  PubMed  CAS  Google Scholar 

  69. Brady, C.S., J.S. Bartholomew, D.J. Burt, M.F. Duggan-Keen, S. Glenville, N. Telford, A.M. Little, J.A. Davidson, P. Jimenez, F. Ruiz-Cabello, F. Garrido, and P.L. Stern. 2000. Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 55:401–411.

    Article  PubMed  CAS  Google Scholar 

  70. Koopman, L.A., W.E. Corver, A.R. van der Slik, M.J. Giphart, and G.J. Fleuren. 2000. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 191:961–976.

    Article  PubMed  CAS  Google Scholar 

  71. Jimenez, P., T. Cabrera, R. Mendez, C. Esparza, J.M. Cozar, M. Tallada, M.A. Lopez-Nevot, F. Ruiz-Cabello, and F. Garrido. 2001. A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A*0301 allele in a prostate carcinoma cell line. Immunogenetics 53:606–610.

    Article  PubMed  CAS  Google Scholar 

  72. Geertsen, R., R. Boni, R. Blasczyk, P. Romero, D. Betts, D. Rimoldi, X. Hong, E. Laine, J. Willers, and R. Dummer. 2002. Loss of single HLA class I allospecificities in melanoma cells due to selective genomic abbreviations. Int J Cancer 99:82–87.

    Article  PubMed  CAS  Google Scholar 

  73. Francke, U., and M.A. Pellegrino. 1977. Assignment of the major histocompatibility complex to a region of the short arm of human chromosome 6. Proc Natl Acad Sci U S A 74:1147–1151.

    Article  PubMed  CAS  Google Scholar 

  74. Marincola, F.M, P. Shamamian, T.B. Simonis, A. Abati, J. Hackett, T. O’Dea, P. Fetsch, J. Yannelli, N.P. Restifo, and J.J. Mule. 1994. Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J Immunother Emphasis Tumor Immunol 16:13–23.

    PubMed  CAS  Google Scholar 

  75. Jimenez, P., J. Canton, A. Collado, T. Cabrera, A. Serrano, L.M. Real, A. Garcia, F. Ruiz-Cabello, and F. Garrido. 1999. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer 83:91–97.

    Article  PubMed  CAS  Google Scholar 

  76. Shiina, T., G. Tamiya, A. Oka, N. Takishima, T. Yamagata, E. Kikkawa, K. Iwata, M. Tomizawa, N. Okuaki, Y. Kuwano, K. Watanabe, Y. Fukuzumi, S. Itakura, C. Sugawara, A. Ono, M. Yamazaki, H. Tashiro, A. Ando, T. Ikemura, E. Soeda, M. Kimura, S. Bahram, and H. Inoko. 1999. Molecular dynamics of MHC genesis unraveled by sequence analysis of the 1,796,938-bp HLA class I region. Proc Natl Acad Sci U S A 96:13282–13287.

    Article  PubMed  CAS  Google Scholar 

  77. Murphy, C., D. Nikodem, K. Howcroft, J.D. Weissman, and D.S. Singer. 1996. Active repression of major histocompatibility complex class I genes in a human neuroblastoma cell line. J Biol Chem 271:30992–30999.

    Article  PubMed  CAS  Google Scholar 

  78. Coral, S., L. Sigalotti, A. Gasparollo, I. Cattarossi, A. Visintin, A. Cattelan, M. Altomonte, and M. Maio. 1999. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR). J Immunother 22:16–24.

    Article  PubMed  CAS  Google Scholar 

  79. Coral, S., L. Sigalotti, M. Altomonte, A. Engelsberg, F. Colizzi, I. Cattarossi, E. Maraskovsky, E. Jager, B. Seliger, and M. Maio. 2002 5-aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res 8:2690–2695.

    PubMed  CAS  Google Scholar 

  80. Fruh, K., and Y. Yang. 1999. Antigen presentation by MHC class I and its regulation by interferon gamma. Curr Opin Immunol 11:76–81.

    Article  PubMed  CAS  Google Scholar 

  81. Ritz, U., F. Momburg, H. Pilch, C. Huber, M.J. Maeurer, and B. Seliger. 2001 Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 19:1211–1220.

    PubMed  CAS  Google Scholar 

  82. Terrazzano, G., M.F. Romano, M.C. Turco, S. Salzano, A. Ottaiano, S. Venuta, S. Fontana, C. Manzo, S. Zappacosta, and E. Carbone. 2000. HLA class I antigen downregulation by interleukin (IL)-10 is predominantly governed by NK-kappaB in the short term and by TAP1+2 in the long term. Tissue Antigens 55:326–332.

    Article  PubMed  CAS  Google Scholar 

  83. Salazar-Onfray, F. 1999. Interleukin-10: a cytokine used by tumors to escape immunosurveillance. Med Oncol 16:86–94.

    PubMed  CAS  Google Scholar 

  84. Seliger, B., D. Atkins, M. Bock, U. Ritz, S. Ferrone, C. Huber, and S. Storkel. 2003. Characterization of HLA class I antigen processing machinery defects in renal cell carcinoma lesions with special emphasis on TAP downregulation. Clin Cancer Res in press.

    Google Scholar 

  85. Corrias, M.V., M. Occhino, M. Croce, A. De Ambrosis, M.P. Pistillo, P. Bocca, V. Pistoia, and S. Ferrini. 2001. Lack of HLA-class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression. Tissue Antigens 57:110–117.

    Article  PubMed  CAS  Google Scholar 

  86. Matsui, M., S. Machida, T. Itani-Yohda, and T. Akatsuka. 2002 Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-gamma. J Gastroenterol Hepatol 17:897–907.

    Article  PubMed  CAS  Google Scholar 

  87. Johnsen, A.K., D.J. Templeton, M. Sy, and C.V. Harding. 1999. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol 163:4224–4231.

    PubMed  CAS  Google Scholar 

  88. Alimonti, J., Q.J. Zhang, R. Gabathuler, G. Reid, S.S. Chen, and W.A. Jefferies. 2000. TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nat Biotechnol 18:515–520.

    Article  PubMed  CAS  Google Scholar 

  89. Murray, J.L., J.M. Hudson, M.I. Ross, H.Z. Zhang, and C.G. Ioannides. 2000. Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: relationship to TAP expression. J Immunother 23:28–35.

    Article  PubMed  CAS  Google Scholar 

  90. Chen, H.L., D. Gabrilovich, R. Tampe, K.R. Girgis, S. Nadaf, and D.P. Carbone. 1996. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet 13:210–213.

    Article  PubMed  CAS  Google Scholar 

  91. Seliger, B., U. Ritz, R. Abele, M. Bock, R. Tampe, G. Sutter, I. Drexler, C. Huber, and S. Ferrone. 2001. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 61:8647–8650.

    PubMed  CAS  Google Scholar 

  92. Corrias, M.V., M. Occhino, M. Croce, A. De Ambrosis, M.P. Pistillo, P. Bocca, V. Pistoia, and S. Ferrini. 2001. Lack of HLA-class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression. Tissue Antigens 57:110–117.

    Article  PubMed  CAS  Google Scholar 

  93. Seliger, B., K. Schreiber, K. Delp, M. Meissner, S. Hammers, T. Reichert, K. Pawlischko, R. Tampe, and C. Huber. 2001. Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines. Tissue Antigens 57:39–45.

    Article  PubMed  CAS  Google Scholar 

  94. Weinman, E., P. Roche, J. Kasperbauer, S. Cha, D. Sargent, J. Cheville, L. Murphy, L. Chen, P. Wettstein, B. Gostout, S. Ferrone, and S. Strome. 2003. Characterization of antigen processing machinery and survivin expression in tonsillar squamous cell carcinoma. Cancer 97:2203–2211.

    Article  PubMed  Google Scholar 

  95. Ogino, T., N. Bandoh, T. Hayashi, N. Miyokawa, Y. Harabuchi, and S. Ferrone. 2003. Association of tapasin and HLA class I antigen downregulation in primary maxillary sinus squamous carcinoma lesions with reduced patients’ survivial. Clin Cancer Res 9:4043–4051.

    PubMed  CAS  Google Scholar 

  96. Imreh, M.P., Q.J. Zhang, P.O. de Campos-Lima, S. Imreh, P. Krausa, M. Browning, G. Klein, and M.G. Masucci. 1995. Mechanisms of allele-selective down-regulation of HLA class I in Burkitt’s lymphoma. Int J Cancer 62:90–96.

    Article  PubMed  CAS  Google Scholar 

  97. Griffioen, M., I.J. Ouwerkerk, V. Harten, and P.I. Schrier. 2000. HLA-B locus-specific downregulation in human melanoma requires enhancer A as well as a sequence element located downstream of the transcription initiation site. Immunogenetics 52:121–128.

    Article  PubMed  CAS  Google Scholar 

  98. Vivier, E., E. Tomasello, and P. Paul. 2002. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition? Curr Opin Immunol 14:306–311.

    Article  PubMed  CAS  Google Scholar 

  99. Bahram, S. 2000. MIC genes: from genetics to biology. Adv Immunol 76:1–60

    PubMed  CAS  Google Scholar 

  100. O’Callaghan, C.A., and J.I. Bell. 1998. Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G. Immunol Rev 163:129–138.

    Article  PubMed  CAS  Google Scholar 

  101. Whiteside, T.L., and H. Rabinowich. 1998. The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother 46:175–184.

    Article  PubMed  CAS  Google Scholar 

  102. Groh, V., R. Rhinehart, H. Secrist, S. Bauer, K.H. Grabstein, and T. Spies. 1999. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A 96:6879–6884.

    Article  PubMed  CAS  Google Scholar 

  103. Seliger, B., H. Abken, and S. Ferrone. 2003. HLA-G and MIC expression in tumors and their role in anti-tumorimmunity. Trends Immunol 24:82–87.

    Article  PubMed  CAS  Google Scholar 

  104. Groh, V., J. Wu, C. Yee, and T. Spies. 2002. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734–738.

    Article  PubMed  CAS  Google Scholar 

  105. June, C.H., J.A. Bluestone, L.M. Nadler, and C.B. Thompson. 1994. The B7 and CD28 receptor families. Immunol Today 15:321–331.

    Article  PubMed  CAS  Google Scholar 

  106. Dorfman, D.M., J.L. Schultze, A. Shahsafaei, S. Michalak, J.G. Gribben, G.J. Freeman, G.S. Pinkus, and L.M. Nadler. 1997. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 90:4297–4306.

    PubMed  CAS  Google Scholar 

  107. Schultze, J.L., A.A. Cardoso, G.J. Freeman, M.J. Seamon, J. Daley, G.S. Pinkus, J.G. Gribben, and L.M. Nadler. 1995. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci U S A 92:8200–8204.

    Article  PubMed  CAS  Google Scholar 

  108. Bixby, D.L., and J.R. Yannelli. 1998. CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer. Int J Cancer 78:685–694.

    Article  PubMed  CAS  Google Scholar 

  109. Habicht, A., M. Lindauer, P. Galmbacher, W. Rudy, J. Gebert, H.K. Schackert, S.C. Meuer, and U. Moebius. 1995. Development of immunogenic colorectal cancer cell lines for vaccination: expression of CD80 (B7.1) is not sufficient to restore impaired primary T cell activation in vitro. Eur J Cancer 31A:2396–2402.

    Article  PubMed  CAS  Google Scholar 

  110. Kaufmann, A.M., L. Gissmann, P. Simms, C. Schreckenberger, and L. Qiao. 2000. Comparison of cytokines and CD80 for enhancement of immunogenicity of cervical cancer cells. Immunobiology 202:339–352.

    PubMed  CAS  Google Scholar 

  111. Hersey, P., and X.D. Zhang. 2001. How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer 1:142–150.

    Article  PubMed  CAS  Google Scholar 

  112. Kim, C.J., T. Prevette, J. Cormier, W. Overwijk, M. Roden, N.P. Restifo, S.A. Rosenberg, and F.M. Marincola. 1997. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J Immunother 20:276–286.

    Article  PubMed  CAS  Google Scholar 

  113. Zhai, Y., J.C. Yang, P. Spiess, M.I. Nishimura, W.W. Overwijk, B. Roberts, N.P. Restifo, and S.A. Rosenberg. 1997. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother 20:15–25.

    Article  PubMed  CAS  Google Scholar 

  114. Dye, E.S., and R.J. North. 1984. Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors. J Leukoc Biol 36:27–37.

    PubMed  CAS  Google Scholar 

  115. Mills, C.D., and R.J. North. 1985. Ly-1+2-suppressor T cells inhibit the expression of passively transferred antitumor immunity by suppressing the generation of cytolytic T cells. Transplantation 39:202–208.

    Article  PubMed  CAS  Google Scholar 

  116. North, R.J., and I. Bursuker. 1984. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2-suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med 159:1295–1311.

    Article  PubMed  CAS  Google Scholar 

  117. North, R.J. 1985. Down-regulation of the antitumor immune response. Adv Cancer Res 45:1–43.

    PubMed  CAS  Google Scholar 

  118. Mosmann, T.R., and R.L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145–173.

    Article  PubMed  CAS  Google Scholar 

  119. Mosmann, T.R., J.H. Schumacher, N.F. Street, R. Budd, A. O’Garra, T.A. Fong, M.W. Bond, K.W. Moore, A. Sher, and D.F. Fiorentino. 1991. Diversity of cytokine synthesis and function of mouse CD4+ T cells. Immunol Rev 123:209–229.

    Article  PubMed  CAS  Google Scholar 

  120. Miescher, S., T.L. Whiteside, S. Carrel, F. von, and V. 1986. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 136:1899–1907.

    PubMed  CAS  Google Scholar 

  121. Miescher, S., M. Stoeck, L. Qiao, C. Barras, L. Barrelet, and F.V. von. 1988. Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumors. Cancer Res 48:6992–6998.

    PubMed  CAS  Google Scholar 

  122. Whiteside, T.L., S. Miescher, L. Moretta, and F.V. von. 1988. Cloning and proliferating precursor frequencies of tumor-infiltrating lymphocytes from human solid tumors. Transplant Proc 20:342–343.

    PubMed  CAS  Google Scholar 

  123. Loeffler, C.M., J.L. Platt, P.M. Anerson, E. Katsanis, J.B. Ochoa, W.J. Urba, D.L. Longo, A.S. Leonard. and A.C. Ochoa. 1991. Antitumor effects of interleukin 2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic muetastasis. Cancer Res 51:2127–2132.

    PubMed  CAS  Google Scholar 

  124. Loeffler, C.M., M.J. Smyth, D.L. Longo, W.C. Kopp, L.K. Harvey, H.R. Tribble, J.E. Tase, W.J. Urba, A.S. Leonard, H.A. Young. and A.C. Ochoa. 1992. Immunoregulation in cancer-bearing hosts: down-regulation of gene expression and cytotoxic function in CD8+ T cells. J Immunol 149:949–956.

    PubMed  CAS  Google Scholar 

  125. Sondak, V.K., P.D. Wagner, S. Shu, and A.E. Chang. 1991. Suppressive effects of visceral tumor on the generation of antitumor T cells for adoptive immunotherapy. Arch Surg 126:442–446.

    PubMed  CAS  Google Scholar 

  126. Gabrilovich, D., T. Ishida, T. Oyama, S. Ran, V. Kravtsov, S. Nadaf, and D.P. Carbone. 1998. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92:4150–4166.

    PubMed  CAS  Google Scholar 

  127. Gabrilovich, D.I., I.F. Ciernik, and D.P. Carbone. 1996. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 170:101–110.

    Article  PubMed  CAS  Google Scholar 

  128. Almand, B., J.I. Clark, E. Nikitina, J. van Beynen, N.R. English, S.C. Knight, D.P. Carbone, and D.I. Gabrilovich. 2001. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678–689.

    PubMed  CAS  Google Scholar 

  129. Zou, W., J. Borvak, S. Wei, T. Isaeva, D.T. Curiel, and T.J. Curiel. 2001. Reciprocal regulation of plasmacytoid dendritic cells and monocytes during viral infection. Eur J Immunol 31:3833–3839.

    Article  PubMed  CAS  Google Scholar 

  130. Zou, W., V. Machelon, A. Coulomb-L’Hermin, J. Borvak, F. Nome, T. Isaeva, S. Wei, R. Krzysiek, I. Durand-Gasselin, A. Gordon, T. Pustilnik, D.T. Curiel, P. Galanaud, F. Capron, D. Emilie, and T.J. Curiel. 2001. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 7:1339–1346.

    Article  PubMed  CAS  Google Scholar 

  131. Albina, J.E., M.D. Caldwell, W.L. Henry, Jr, and C.D. Mills. 1989. Regulation of macrophage functions by L-arginine. J Exp Med 169:1021–1029.

    Article  PubMed  CAS  Google Scholar 

  132. Mori, M., and T. Gotoh. 2000. Regulation of nitric oxide production by arginine metabolic enzymes. Biochem Biophys Res Commun 275:715–719.

    Article  PubMed  CAS  Google Scholar 

  133. McHugh, R.S., and E.M. Shevach. 2002. Cutting edge: depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. J Immunol 168:5979–5983.

    PubMed  CAS  Google Scholar 

  134. Sutmuller, R.P., L.M. van Duivenvoorde, A. van Elsas, T.N. Schumacher, M.E. Wildenberg, J.P. Allison, R.E. Toes, R. Offringa, and C.J. Melief. 2001. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823–832.

    Article  PubMed  CAS  Google Scholar 

  135. Antony, P.A., and N.P. Restifo. 2002. Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy? J Immunother 25:202–206.

    Article  PubMed  CAS  Google Scholar 

  136. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L.E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J. Cerottini, J. Tschopp. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363–1366.

    Article  PubMed  CAS  Google Scholar 

  137. Niehans, G.A., T. Brunner, S.P. Frizelle, J.C. Liston, C.T. Salerno, D.J. Knapp, D.R. Green, and R.A. Kratzke. 1997. Human lung carcinomas express Fas ligand. Cancer Res 57:1007–1012.

    PubMed  CAS  Google Scholar 

  138. O’Connell, J., M.W. Bennett, G.C. O’Sullivan, J.K. Collins, and F. Shanahan. 1999. The Fas counterattack: cancer as a site of immune privilege. Immunol Today 20:46–52.

    Article  PubMed  CAS  Google Scholar 

  139. Hersey, P. 1999. Impediments to successful immunotherapy. Pharmacol Ther 81:111–119.

    Article  PubMed  CAS  Google Scholar 

  140. Saito, T., I. Kuss, G. Dworacki, W. Gooding, J.T. Johnson, and T.L. Whiteside. 1999. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res 5:1263–1273.

    PubMed  CAS  Google Scholar 

  141. Frank, S.J., L.E. Samelson, and R.D. Klausner. 1990. The structure and signalling functions of the invariant T cell receptor components. Semin Immunol 2:89–97.

    PubMed  CAS  Google Scholar 

  142. Weiss, A., D. Desai, M. Graber, J. Picus, and G. Koretzky. 1991. The regulation of T-cell antigen receptor signal transduction function. Transplant Proc 23:32–33.

    PubMed  CAS  Google Scholar 

  143. Weissman, A.M., M. Baniyash, D. Hou, L.E. Samelson, W.H. Burgess, and R.D. Klausner. 1988. Molecular cloning of the zeta chain of the T cell antigen receptor. Science 239:1018–1021.

    Article  PubMed  CAS  Google Scholar 

  144. Bockenstedt, L.K., M.A. Goldsmith, G.A. Koretzky, and A. Weiss. 1987. The activation of T lymphocytes. Rheum Dis Clin North Am 13:411–430.

    PubMed  CAS  Google Scholar 

  145. Fraser, J.D., D. Straus, and A. Weiss. 1993. Signal transduction events leading to T-cell lymphokine gene expression. Immunol Today 14:357–362.

    Article  PubMed  CAS  Google Scholar 

  146. Quill, H., and R.H. Schwartz. 1987. Stimulation of normal inducer T cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness. J Immunol 138:3704–3712.

    PubMed  CAS  Google Scholar 

  147. Quill, H., M.P. Riley, E.A. Cho, J.E. Casnellie, J.C. Reed, and T. Torigoe. 1992. Anergic Th1 cells express altered levels of the protein tyrosine kinases p56lck and p59 fyn. J Immunol 149:2887–2893.

    PubMed  CAS  Google Scholar 

  148. Jenkins, M.K., and R.H. Schwartz. 1987. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 165:302–319.

    Article  PubMed  CAS  Google Scholar 

  149. Cho, E.A., M.P. Riley, A.L. Sillman, H. Quill. 1993. Altered protein tyrosine phosphorylation in anergic Th1 cells. J Immunol 151:20–28.

    PubMed  CAS  Google Scholar 

  150. Gajewski, T.F., D. Qian, P. Fields, and F.W. Fitch. 1994. Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways. Proc Natl Acad Sci U S A 91:38–42.

    Article  PubMed  CAS  Google Scholar 

  151. Fields, P.E., T.F. Gajewski, and F.W. Fitch. 1996. Blocked Ras activation in anergic CD4+ T cells. Science 271:1276–1278.

    Article  PubMed  CAS  Google Scholar 

  152. Mondino, A., C.D. Whaley, D.R. DeSilva, W. Li, M.K. Jenkins, and D.L. Mueller. 1996. Defective transcription of the IL-2 gene is associated with impaired expression of c-Fos, FosB, and JunB in anergic T helper 1 cells. J Immunol 157:2048–2057.

    PubMed  CAS  Google Scholar 

  153. Mizoguchi, H., J.J. O’Shea, D.L. Longo, C.M. Loeffler, D.W. McVicar, and A.C. Ochoa. 1992. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795–1798.

    Article  PubMed  CAS  Google Scholar 

  154. Li, X., J. Liu, J.K. Park, T.A. Hamilton, P. Rayman, E. Klein, M. Edinger, R. Tubbs, R. Bukowski, and J. Finke. 1994. T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report. Cancer Res 54:5424–5429.

    PubMed  CAS  Google Scholar 

  155. Ghosh, P., A. Sica, H.A. Young, J. Ye, J.L. Franco, R.H. Wiltrout, D.L. Longo, N.R. Rice, K.L. Komschlies. 1994. Alterations in NF kappa B/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy. Cancer Res 54:2969–2972.

    PubMed  CAS  Google Scholar 

  156. Young, H.A., and P. Ghosh. 1997. Molecular regulation of cytokine gene expression: interferon-gamma as a model system. Prog Nucleic Acid Res Mol Biol 56:109–127.

    PubMed  CAS  Google Scholar 

  157. Ghosh, P., K.L. Komschlies, M. Cippitelli, D.L. Longo, J. Subleski, J. Ye, A. Sica, H.A. Young, R.H. Wiltrout, and A.C. Ochoa. 1995. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst 87:1478–1483.

    Article  PubMed  CAS  Google Scholar 

  158. Buggins, A.G., W.J. Hirst, A. Pagliuca, and G.J. Mufti. 1998. Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies. Br J Haematol 100:784–792.

    Article  PubMed  CAS  Google Scholar 

  159. Finke, J.H., A.H. Zea, J. Stanley, D.L. Longo, H. Mizoguchi, R.R. Tubbs, R.H. Wiltrout, J.J. O’Shea, S. Kudoh, and E. Klein. 1993. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 53:5613–5616.

    PubMed  CAS  Google Scholar 

  160. Gunji, Y., S. Hori, T. Aoe, T. Asano, T. Ochiai, K. Isono, and T. Saito. 1994. High frequency of cancer patients with abnormal assembly of the T cell receptor-CD3 complex in peripheral blood T lymphocytes. Jpn J Cancer Res 85:1189–1192.

    PubMed  CAS  Google Scholar 

  161. Rabinowich, H., Y. Suminami, T.E. Reichert, P. Crowley-Nowick, M. Bell, R. Edwards, and T.L. Whiteside. 1996. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 68:276–284.

    Article  PubMed  CAS  Google Scholar 

  162. Rossi, E., E. Matutes, R. Morilla, K. Owusu-Ankomah, A.M. Heffernan, and D. Catovsky. 1996. Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia 10:494–497.

    PubMed  CAS  Google Scholar 

  163. Kolenko, V., Q. Wang, M.C. Riedy, J. O’Shea, J. Ritz, M.K. Cathcart, P. Rayman, R. Tubbs, M. Edinger, A. Novick, R. Bukowski, and J. Finke. 1997. Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. J Immunol 159:3057–3067.

    PubMed  CAS  Google Scholar 

  164. Nakagomi, H., M. Petersson, I. Magnusson, C. Juhlin, M. Matsuda, H. Mellstedt, J.L. Taupin, E. Vivier, P. Anderson, and R. Kiessling. 1993. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 53:5610–5612.

    PubMed  CAS  Google Scholar 

  165. Bukowski, R.M., P. Rayman, R. Uzzo, T. Bloom, K. Sandstrom, D. Peereboom, T. Olencki, G.T. Budd, D. McLain, P. Elson, A. Novick, and J.H. Finke. 1998. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy. Clin Cancer Res 4:2337–2347.

    PubMed  CAS  Google Scholar 

  166. Kono, K., M.E. Ressing, R.M. Brandt, C.J. Melief, R.K. Potkul, B. Andersson, M. Petersson, W.M. Kast, and R. Kiessling. 1996. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 2:1825–1828.

    PubMed  CAS  Google Scholar 

  167. Zea, A.H., B.D. Curti, D.L. Longo, W.G. Alvord, S.L. Strobl, H. Mizoguchi, S.P. Creekmore, J.J. O’Shea, G.C. Powers, W.J. Urba, and A.C. Ochoa. 1995. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1:1327–1335.

    PubMed  CAS  Google Scholar 

  168. Reichert, T.E., R. Day, E.M. Wagner, and T.L. Whiteside. 1998. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 58:5344–5347.

    PubMed  CAS  Google Scholar 

  169. Massaia, M., C. Attisano, E. Beggiato, A. Bianchi, and A. Pileri. 1994. Correlation between disease activity and T-cell CD3 zeta chain expression in a B-cell lymphoma. Br J Haematol 88:886–888.

    PubMed  CAS  Google Scholar 

  170. Renner, C., S. Ohnesorge, G. Held, S. Bauer, W. Jung, J.P. Pfitzenmeier, and M. Pfreundschuh. 1996. T cells from patients with Hodgkin’s disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood 88:236–241.

    PubMed  CAS  Google Scholar 

  171. Gratama, J.W., A.H. Zea, R.L. Bolhuis, and A.C. Ochoa. 1999. Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy. Cancer Immunol Immunother 48:263–269.

    Article  PubMed  CAS  Google Scholar 

  172. Otsuji, M., Y. Kimura, T. Aoe, Y. Okamoto, and T. Saito. 1996. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci U S A 93:13119–13124.

    Article  PubMed  CAS  Google Scholar 

  173. Kono, K., F. Salazar-Onfray, M. Petersson, J. Hansson, G. Masucci, K. Wasserman, T. Nakazawa, P. Anderson, and R. Kiessling. 1996. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol 26:1308–1313.

    Article  PubMed  CAS  Google Scholar 

  174. Schmielau, J., and O.J. Finn. 2001. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 61:4756–4760.

    PubMed  CAS  Google Scholar 

  175. Kolenko, V., P. Rayman, B. Roy, M.K. Cathcart, J. O’Shea, R. Tubbs, L. Rybicki, R. Bukowski, and J. Finke. 1999. Downregulation of JAK3 protein levels in T lymphocytes by prostaglandin E2 and other cyclic adenosine monophosphate-elevating agents: impact on interleukin-2 receptor signaling pathway. Blood 93:2308–2318.

    PubMed  CAS  Google Scholar 

  176. Gastman, B.R., D.E. Johnson, T.L. Whiteside, and H. Rabinowich. 1999. Caspase-mediated degradation of T-cell receptor zeta-chain. Cancer Res 59:1422–1427.

    PubMed  CAS  Google Scholar 

  177. Rabinowich, H., T.E. Reichert, Y. Kashii, B.R. Gastman, M.C. Bell, and T.L. Whiteside. 1998. Lymphocyte apoptosis induced by Fas li. J Clin Invest 101:2579–2588.

    PubMed  CAS  Google Scholar 

  178. Uzzo, R.G., P. Rayman, V. Kolenko, P.E. Clark, M.K. Cathcart, T. Bloom, A.C. Novick, R.M. Bukowski, T. Hamilton, and J.H. Finke. 1999. Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. J Clin Invest 104:769–776.

    Article  PubMed  CAS  Google Scholar 

  179. Uzzo, R.G., P. Rayman, V. Kolenko, P.E. Clark, T. Bloom, A.M. Ward, L. Molto, C. Tannenbaum, L.J. Worford, R. Bukowski, R. Tubbs, E.D. Hsi, N.H. Bander, A.C. Novick, and J.H. Finke. 1999. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res 5:1219–1229.

    PubMed  CAS  Google Scholar 

  180. Uzzo, R.G., P.E. Clark, P. Rayman, T. Bloom, L. Rybicki, A.C. Novick, R.M. Bukowski, and J.H. Finke. 1999. Alterations in NFkappaB activation in T lymphocytes of patients with renal cell carcinoma. J Natl Cancer Inst 91:718–721.

    Article  PubMed  CAS  Google Scholar 

  181. Mellor, A.L., D.B. Keskin, T. Johnson, P. Chandler, and D.H. Munn. 2002. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol 168:3771–3776.

    PubMed  CAS  Google Scholar 

  182. Munn, D.H., M.D. Sharma, J.R. Lee, K.G. Jhaver, T.S. Johnson, D.B. Keskin, B. Marshall, P. Chandler, S.J. Antonia, R. Burgess, C.L. Slingluff, Jr, and A.L. Mellor. 2002. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297:1867–1870.

    Article  PubMed  CAS  Google Scholar 

  183. Rodriguez, P.C., A.H. Zea, K.S. Culotta, J. Zabalueta, J.B. Ochoa, and A.C. Ochoa. 2002. Regulation of T cell receptor CD3 zeta chain expression by L-arginine. J Biol Chem 277:21123–21129.

    Article  PubMed  CAS  Google Scholar 

  184. Taheri, F., J.B. Ochoa, Z. Faghiri, K. Culotta, H.J. Park, M.S. Lan, A.H. Zea, and A.C. Ochoa. 2001. L-Arginine regulates the expression of the T-cell receptor zeta chain (CD3zeta) in Jurkat cells. Clin Cancer Res 7:958s–965s

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, 533 Bolivar Street, New Orleans, LA, 70112

    Arnold H. Zea, Paulo C. Rodriguez & Augusto C. Ochoa

  2. Department of Immunology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York, 14263

    Michael Campoli & Soldano Ferrone

  3. Department of Pediatrics, Louisiana State University Health Sciences Center, 533 Bolivar Street, New Orleans, LA, 70112

    Augusto C. Ochoa

Authors
  1. Michael Campoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Soldano Ferrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arnold H. Zea
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paulo C. Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Augusto C. Ochoa
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Vaccine Branch, National Cancer Institute, Bethesda Naval Hospital Bethesda, MD, USA

    Samir N. Khleif

  2. King Hussein Cancer Center, Amman, Jordan

    Samir N. Khleif

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Kluwer Academic Publishers

About this chapter

Cite this chapter

Campoli, M., Ferrone, S., Zea, A.H., Rodriguez, P.C., Ochoa, A.C. (2005). Mechanisms of Tumor Evasion. In: Khleif, S.N. (eds) Tumor Immunology and Cancer Vaccines. Cancer Treatment and Research, vol 123. Springer, Boston, MA. https://doi.org/10.1007/0-387-27545-2_3

Download citation

  • DOI: https://doi.org/10.1007/0-387-27545-2_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4020-8119-4

  • Online ISBN: 978-0-387-27545-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation